Zetagen Therapeutics, a clinical-stage biotech developing breast cancer treatments, raised a $12.9 million Series B1 round, CEO Joe Loy tells Axios exclusively.
What's next: The financing will help Zetagen advance its lead drug candidate to Phase 3 trials, which could begin as soon as Q4 2026.
